EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings

Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.391
https://www.valueinhealthjournal.com/article/S1098-3015(24)00506-0/fulltext
Section Title :
Section Order : 11739
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00506-0&doi=10.1016/j.jval.2024.03.391
HEOR Topics :
Tags :
Regions :